Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10199294 | 0.86 | NPC1 (0.41) | NPC1RAB9ASCN4ASMN1; SMN2PSMB5 | |
| SCHEMBL10120019 | 0.85 | AAK1 (0.50) | NPC1RAB9ASCN4ASMN1; SMN2AAK1 | |
| SCHEMBL20100917 | 0.84 | ESR1 (0.40) | NPC1RAB9ASCN4ASMN1; SMN2PSMB5 | |
| SCHEMBL21036863 | 0.83 | PIK3CD (0.40) | NPC1RAB9APDE10AAAK1ALDH1A1 | |
| SCHEMBL1869386 | 0.83 | ALDH1A1 (0.47) | NPC1RAB9ASMN1; SMN2PDE10AUGT2B7 | |
| SCHEMBL2609300 | 0.80 | HTR3A (0.46) | SMN1; SMN2PDE10AAAK1ALDH1A1MEN1 | |
| SCHEMBL21195656 | 0.80 | NPC1 (0.43) | NPC1RAB9ASCN4ASMN1; SMN2PSMB5 | |
| SCHEMBL10122186 | 0.80 | NPC1 (0.43) | NPC1RAB9ASCN4ASMN1; SMN2PSMB5 | |
| SCHEMBL2667929 | 0.80 | CYP1A2 (0.59) | NPC1RAB9ASMN1; SMN2PSMB5AAK1 | |
| SCHEMBL1102403 | 0.80 | CYP1A2 (0.59) | NPC1RAB9ASCN4ASMN1; SMN2PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918575-B2 | PZA and cytochrome Bc1 inhibitor combination treatment | Janssen Sciences Ireland Unlimited Company (IE) | 2024-03-05 | — | — | US | disclosed |
| US-11918575-B2 | PZA and cytochrome Bc1 inhibitor combination treatment | Janssen Sciences Ireland Unlimited Company (IE) | 2024-03-05 | — | — | US | disclosed |
| WO-2023235753-A2 | ALDH2 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230014173-A1 | Antibacterial Compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2023-01-19 | — | — | US | disclosed |
| US-11180472-B2 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2021-11-23 | — | — | US | disclosed |
| US-11149110-B2 | Nanoparticles for use in light emitting applications | CHROMITION LIMITED (GB) | 2021-10-19 | — | — | US | disclosed |
| US-20210040260-A1 | NANOPARTICLES | CHROMITION LTD (GB) | 2021-02-11 | — | — | US | disclosed |
| US-20200239434-A1 | ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2020-07-30 | — | — | US | disclosed |
| US-10703857-B2 | Nanoparticles | CHROMITION LIMITED (GB) | 2020-07-07 | — | — | US | disclosed |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110070196-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064696-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | MSD K.K. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-7452911-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-11-18 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180472-B2 | Antibacterial compounds | FDPS, SQOR, NDUFS3 | NPC1 1147/4885RAB9A 3094/4885SCN4A 4715/4885 |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | NPC1 36/4885RAB9A 3036/4885SCN4A 4001/4885 |
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TLR2, TLR3, TLR4 | NPC1 1746/4885RAB9A 4207/4885SCN4A 3838/4885 |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | MTTP, CETP, FABP2 | NPC1 37/4885RAB9A 2515/4885SCN4A 2281/4885 |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | NPC1 36/4885RAB9A 3036/4885SCN4A 4001/4885 |
| US-20230014173-A1 | Antibacterial Compounds | FDPS, SQOR, NDUFS3 | NPC1 1147/4885RAB9A 3094/4885SCN4A 4715/4885 |
| US-20110070196-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | NPC1 34/4885RAB9A 3060/4885SCN4A 3949/4885 |
| US-20200239434-A1 | ANTIBACTERIAL COMPOUNDS | FDPS, SQOR, NDUFS3 | NPC1 1147/4885RAB9A 3094/4885SCN4A 4715/4885 |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | NPC1 34/4885RAB9A 3060/4885SCN4A 3949/4885 |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | NPC1 34/4885RAB9A 3060/4885SCN4A 3949/4885 |
| US-20110064696-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | NPC1 34/4885RAB9A 3060/4885SCN4A 3949/4885 |
| US-11918575-B2 | PZA and cytochrome Bc1 inhibitor combination treatment | CYC1, MT-ND1, MT-CO1 | NPC1 613/4885RAB9A 3467/4885SCN4A 4375/4885 |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | NPC1 34/4885RAB9A 3060/4885SCN4A 3949/4885 |
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | PYCR1, CHRM1, MTR | NPC1 3130/4885RAB9A 4390/4885SCN4A 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.